Trials / Terminated
TerminatedNCT04882072
A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Takayasu Arteritis
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Janssen Pharmaceutical K.K. · Industry
- Sex
- All
- Age
- 15 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of ustekinumab compared to placebo, in combination with oral glucocorticoid (GC) taper regimen, in participants with relapsing Takayasu Arteritis (TAK).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ustekinumab | Participants will receive IV infusion and SC injection of ustekinumab. |
| OTHER | Placebo | Participants will receive IV infusion and SC injection of matching placebo. |
| DRUG | Glucorticoid Taper Regimen | Glucocorticoid will be administered orally. |
Timeline
- Start date
- 2021-09-15
- Primary completion
- 2023-05-25
- Completion
- 2023-05-25
- First posted
- 2021-05-11
- Last updated
- 2025-04-29
- Results posted
- 2024-12-02
Locations
27 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04882072. Inclusion in this directory is not an endorsement.